• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

68Ga 标记的 exendin-3，一种用于 PET 检测胰岛素瘤的新型试剂。

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.

机构信息

Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

出版信息

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1345-55. doi: 10.1007/s00259-009-1363-y. Epub 2010 Jan 29.

DOI:10.1007/s00259-009-1363-y
PMID:20111963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2886138/
Abstract

PURPOSE

Insulinomas are neuroendocrine tumours derived from pancreatic beta-cells. The glucagon-like peptide 1 receptor (GLP-1R) is expressed with a high incidence (>90%) and high density in insulinomas. Glucagon-like peptide 1 (GLP-1), the natural ligand of GLP-1R, is rapidly degraded in vivo. A more stable agonist of GLP-1R is exendin-3. We investigated imaging of insulinomas with DOTA-conjugated exendin-3 labelled with (68)Ga.

METHODS

Targeting of insulinomas with [Lys(40)(DOTA)]exendin-3 labelled with either (111)In or (68)Ga was investigated in vitro using insulinoma tumour cells (INS-1). [Lys(40)((111)In-DTPA)]Exendin-3 was used as a reference in this study. In vivo targeting was investigated in BALB/c nude mice with subcutaneous INS-1 tumours. PET imaging was performed using a preclinical PET/CT scanner.

RESULTS

In vitro exendin-3 specifically bound and was internalized by GLP-1R-positive cells. In BALB/c nude mice with subcutaneous INS-1 tumours a high uptake of [Lys(40)((111)In-DTPA)]exendin-3 in the tumour was observed (33.5 +/- 11.6%ID/g at 4 h after injection). Uptake was specific, as determined by coinjection of an excess of unlabelled [Lys(40)]exendin-3 (1.8 +/- 0.1%ID/g). The pancreas also exhibited high and specific uptake (11.3 +/- 1.0%ID/g). High uptake was also found in the kidneys (144 +/- 24%ID/g) and this uptake was not receptor-mediated. In this murine tumour model optimal targeting of the GLP-1R expressing tumour was obtained at exendin doses < or =0.1 microg. Remarkably, tumour uptake of (68)Ga-labelled [Lys(40)(DOTA)]exendin-3 was lower (8.9 +/- 3.1%ID/g) than tumour uptake of (111)In-labelled [Lys(40)(DTPA)]exendin-3 (25.4 +/- 7.2%ID/g). The subcutaneous tumours were clearly visualized by small-animal PET imaging after injection of 3 MBq of [Lys(40)((68)Ga-DOTA)]exendin-3.

CONCLUSION

[Lys(40)((68)Ga-DOTA)]Exendin-3 specifically accumulates in insulinomas, although the uptake is lower than that of [Lys(40)((111)In-DTPA)]exendin-3. Therefore, [Lys(40)((68)Ga-DOTA)]exendin-3 is a promising tracer to visualize insulinomas with PET.

摘要

目的

胰岛素瘤是源自胰岛β细胞的神经内分泌肿瘤。胰高血糖素样肽 1 受体 (GLP-1R) 在胰岛素瘤中表达具有高发生率 (>90%)和高密度。GLP-1 是 GLP-1R 的天然配体，在体内迅速降解。GLP-1R 的一种更稳定的激动剂是 exendin-3。我们研究了用 DOTA 缀合的 exendin-3 标记的 (68)Ga 对胰岛素瘤的成像。

方法

使用胰岛素瘤肿瘤细胞 (INS-1) 在体外研究了用 (111)In 或 (68)Ga 标记的 [Lys(40)(DOTA)]exendin-3 的靶向性。在这项研究中，[Lys(40)((111)In-DTPA)]Exendin-3 被用作参考。在皮下植入 INS-1 肿瘤的 BALB/c 裸鼠中进行体内靶向研究。使用临床前 PET/CT 扫描仪进行 PET 成像。

结果

体外实验中，外源性 exendin-3 特异性结合并被 GLP-1R 阳性细胞内化。在皮下植入 INS-1 肿瘤的 BALB/c 裸鼠中，观察到 [Lys(40)((111)In-DTPA)]exendin-3 在肿瘤中的高摄取 (注射后 4 小时为 33.5 +/- 11.6%ID/g)。通过共注射过量未标记的 [Lys(40)]exendin-3 (1.8 +/- 0.1%ID/g) 确定摄取是特异性的。胰腺也表现出高特异性摄取 (11.3 +/- 1.0%ID/g)。肾脏也有高摄取 (144 +/- 24%ID/g)，但这种摄取不是受体介导的。在这种小鼠肿瘤模型中，外源性 exendin-3 的最佳靶向剂量小于或等于 0.1 微克。值得注意的是，(68)Ga 标记的 [Lys(40)(DOTA)]exendin-3 的肿瘤摄取率 (8.9 +/- 3.1%ID/g) 低于 (111)In 标记的 [Lys(40)(DTPA)]exendin-3 的肿瘤摄取率 (25.4 +/- 7.2%ID/g)。注射 3MBq [Lys(40)((68)Ga-DOTA)]exendin-3 后，通过小动物 PET 成像可以清楚地观察到皮下肿瘤。

结论

[Lys(40)((68)Ga-DOTA)]Exendin-3 特异性积聚在胰岛素瘤中，尽管摄取量低于 [Lys(40)((111)In-DTPA)]exendin-3。因此，[Lys(40)((68)Ga-DOTA)]exendin-3 是一种有前途的示踪剂，可用于 PET 可视化胰岛素瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/740ee90e76c0/259_2009_1363_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/b414755163a3/259_2009_1363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/4726fac1f519/259_2009_1363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/b59df47c999f/259_2009_1363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/2fbae648cdb4/259_2009_1363_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/f4f3f530618a/259_2009_1363_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/d6f593acc080/259_2009_1363_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/d6ed50b91099/259_2009_1363_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/4020d8321ef6/259_2009_1363_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/740ee90e76c0/259_2009_1363_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/b414755163a3/259_2009_1363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/4726fac1f519/259_2009_1363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/b59df47c999f/259_2009_1363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/2fbae648cdb4/259_2009_1363_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/f4f3f530618a/259_2009_1363_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/d6f593acc080/259_2009_1363_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/d6ed50b91099/259_2009_1363_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/4020d8321ef6/259_2009_1363_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1649/2886138/740ee90e76c0/259_2009_1363_Fig9_HTML.jpg

相似文献

1
68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.68Ga 标记的 exendin-3，一种用于 PET 检测胰岛素瘤的新型试剂。
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1345-55. doi: 10.1007/s00259-009-1363-y. Epub 2010 Jan 29.
2
Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.放射性标记的 GLP-1 类似物用于胰岛素瘤的体内靶向。
Contrast Media Mol Imaging. 2012 Mar-Apr;7(2):160-6. doi: 10.1002/cmmi.475.
3
New Radiolabeled Exendin Analogues Show Reduced Renal Retention.新型放射性标记 Exendin 类似物显示出减少的肾脏滞留。
Mol Pharm. 2023 Jul 3;20(7):3519-3528. doi: 10.1021/acs.molpharmaceut.3c00117. Epub 2023 Jun 2.
4
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.[赖氨酸40（己二胺四乙酸-铟-111）氨基]艾塞那肽-4，一种非常有前景的靶向胰高血糖素样肽-1（GLP-1）受体的配体。
J Nucl Med. 2006 Dec;47(12):2025-33.
5
Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.[(68)Ga]Ga-DO3A-VS-Cys(40)-艾塞那肽-4用于胰岛素瘤成像的临床前评估。
Nucl Med Biol. 2014 Jul;41(6):471-6. doi: 10.1016/j.nucmedbio.2014.03.017. Epub 2014 Mar 29.
6
[Ga]Ga-NOTA-MAL-Cys-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma.[镓 68]Ga-NOTA-MAL-Cys-Exendin-4，一种用于检测胰岛素瘤的潜在 GLP-1R 靶向正电子发射断层扫描（PET）示踪剂。
Nucl Med Biol. 2019 Jul-Aug;74-75:19-24. doi: 10.1016/j.nucmedbio.2019.08.002. Epub 2019 Aug 16.
7
18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.18F 标记的 exendin-4 类似物用于胰岛素瘤中 GLP-1 的 PET 成像。
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):463-73. doi: 10.1007/s00259-011-1980-0. Epub 2011 Dec 15.
8
Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.用 ⁶⁸Ga-DOTA-Exendin-4 PET/CT 定位隐匿性胰岛素瘤：一项初步研究。
J Nucl Med. 2015 Jul;56(7):1075-8. doi: 10.2967/jnumed.115.157768. Epub 2015 May 21.
9
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.基于 exendin-4 的放射性药物用于胰高血糖素样肽-1 受体 PET/CT 和 SPECT/CT。
J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914.
10
PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue.¹⁸F-FBEM-EM3106B 用于胰岛素瘤的 PET 显像，这是一种新型 GLP-1 类似物。
Mol Pharm. 2011 Oct 3;8(5):1775-82. doi: 10.1021/mp200141x. Epub 2011 Aug 19.

引用本文的文献

1
[Ga] labelled Exendin for radioguided surgery of intrapancreatic insulin producing lesions in patients with congenital hyperinsulinism.[镓]标记的艾塞那肽用于先天性高胰岛素血症患者胰腺内胰岛素分泌性病变的放射性引导手术。
EJNMMI Res. 2025 Aug 12;15(1):107. doi: 10.1186/s13550-025-01294-8.
2
Pb in targeted radionuclide therapy: a review.靶向放射性核素治疗中的铅：综述
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.
3
GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades.

本文引用的文献

1
Glucagon-like peptide 1-receptor scans to localize occult insulinomas.胰高血糖素样肽-1受体扫描用于定位隐匿性胰岛素瘤。
N Engl J Med. 2008 Aug 14;359(7):766-8. doi: 10.1056/NEJMc0802045.
2
Occult sporadic insulinoma: localization and surgical strategy.隐匿性散发性胰岛素瘤：定位与手术策略
World J Gastroenterol. 2008 Feb 7;14(5):657-65. doi: 10.3748/wjg.14.657.
3
Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.用（111）铟标记的胆囊收缩素-8（CCK8）和（111）铟标记的小胃泌素靶向CCK（2）受体剪接变体
使用经过验证的单克隆抗体检测689例神经内分泌肿瘤中的GLP-1R状态及其与生长抑素受体闪烁显像、胰岛素分泌和组织学分级的相关性。
Virchows Arch. 2025 Apr 26. doi: 10.1007/s00428-025-04098-2.
4
Characterization of the Pancreatic Neuroendocrine Neoplasm Immune Microenvironment.胰腺神经内分泌肿瘤免疫微环境的特征
Cancer Med. 2025 Apr;14(7):e70798. doi: 10.1002/cam4.70798.
5
Characterization and comparison of insulinoma tumor model and pancreatic damage caused by the tumor, and identification of possible markers.胰岛素瘤肿瘤模型的特征和比较，以及肿瘤引起的胰腺损伤，并鉴定可能的标志物。
Mol Biol Rep. 2024 Jan 16;51(1):109. doi: 10.1007/s11033-023-08942-z.
6
Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.胰高血糖素样肽-1受体分子成像中的诊疗一体化：挑战与新机遇
Front Mol Biosci. 2023 Sep 15;10:1210347. doi: 10.3389/fmolb.2023.1210347. eCollection 2023.
7
Translational challenges in pancreatic neuroendocrine tumor immunotherapy.胰腺神经内分泌肿瘤免疫治疗中的转化挑战。
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188640. doi: 10.1016/j.bbcan.2021.188640. Epub 2021 Oct 22.
8
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents?基于小肽的胰高血糖素样肽-1受体（GLP-1R）配体：一种降低放射性标记的GLP-1R靶向剂肾脏摄取的方法？
EJNMMI Radiopharm Chem. 2021 Aug 25;6(1):29. doi: 10.1186/s41181-021-00136-x.
9
Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.非侵入性β细胞成像：可视化、定量分析及超越。
Front Endocrinol (Lausanne). 2021 Jun 25;12:714348. doi: 10.3389/fendo.2021.714348. eCollection 2021.
10
Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.镓-正电子发射断层扫描/计算机断层扫描-神经调节素原-4 可提高局灶性先天性高胰岛素血症的检出率。
J Nucl Med. 2022 Feb;63(2):310-315. doi: 10.2967/jnumed.121.262327. Epub 2021 Jul 2.
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):386-92. doi: 10.1007/s00259-007-0604-1. Epub 2007 Oct 13.
4
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.[赖氨酸40（己二胺四乙酸-铟-111）氨基]-艾塞那肽-4是一种用于胰岛素瘤的胰高血糖素样肽-1受体靶向治疗的高效放射治疗剂。
Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965.
5
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.68Ga-DOTATOC正电子发射断层扫描（PET）与111铟-二乙三胺五醋酸奥曲肽（Octreoscan）单光子发射计算机断层扫描（SPECT）在神经内分泌肿瘤患者中的比较。
Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26. doi: 10.1007/s00259-007-0450-1. Epub 2007 May 23.
6
Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.氟-18-L-二羟基苯丙氨酸（18F-DOPA）正电子发射断层扫描作为定位成年患者胰岛素瘤或β细胞增生的一种工具。
J Clin Endocrinol Metab. 2007 Apr;92(4):1237-44. doi: 10.1210/jc.2006-1479. Epub 2007 Jan 16.
7
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?放射性镓标记的DOTA偶联生长抑素类似物是否优于其他放射性金属标记的同类物？
Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93. doi: 10.1007/s00259-006-0317-x. Epub 2007 Jan 16.
8
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.[赖氨酸40（己二胺四乙酸-铟-111）氨基]艾塞那肽-4，一种非常有前景的靶向胰高血糖素样肽-1（GLP-1）受体的配体。
J Nucl Med. 2006 Dec;47(12):2025-33.
9
A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.一种用于特定胰高血糖素样肽-1结合位点体内成像的新技术：小型啮齿动物的初步结果。
Regul Pept. 2006 Dec 10;137(3):162-7. doi: 10.1016/j.regpep.2006.07.005. Epub 2006 Aug 22.
10
Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours.胰腺神经内分泌肿瘤定位中的血管造影和动脉刺激静脉采血
Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):229-39. doi: 10.1016/j.beem.2004.10.002.